SCHEMBL5380508

SCHEMBL5380508

Cc1nn(-c2ccccc2)c(C)c1S(=O)(=O)c1ncn(C(=O)N(C)C)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.55
KDM4E B2RXH2 1/20 0.55
APEX1 P27695 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 2/20 0.43
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
PDE4D Q08499 1/20 0.39
HTT P42858 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5371737 0.76 LMNA (0.52) POLBKDM4EAPEX1TDP1SMN1; SMN2
SCHEMBL5376972 0.74 ALDH1A1 (0.45) KDM4EMAPK1MAPTALDH1A1NPC1
SCHEMBL5396559 0.74 ALDH1A1 (0.38) POLBMAPTALDH1A1HPGDNPSR1
SCHEMBL5384803 0.73 KMT2A (0.44) KDM4ETDP1SMN1; SMN2LMNAMAPK1
SCHEMBL3066671 0.73 POLB (1.00) POLBKDM4EAPEX1TDP1SMN1; SMN2
Benzene SCHEMBL28024132 0.73 POLB (1.00) POLBKDM4EAPEX1TDP1SMN1; SMN2
SCHEMBL5384837 0.71 KMT2A (0.41) KDM4ESMN1; SMN2LMNAMAPK1ALDH1A1
SCHEMBL5376966 0.71 DAGLA (0.43) POLBSMN1; SMN2MAPTNPC1MEN1
SCHEMBL5371714 0.71 DPP4 (0.39) TDP1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5381321 0.70 ALDH1A1 (0.42) POLBKDM4ETDP1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2004-09-23 US disclosed
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI CO., LTD. (JP) 2003-03-27 US disclosed
EP-1258480-A1 Pharmaceutical use of N-Carbamoylazole derivatives Eisai Co., Ltd. (JP) 2002-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 POLB 4436/4885KDM4E 698/4885APEX1 4378/4885
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 POLB 4436/4885KDM4E 698/4885APEX1 4378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.